Nurix Therapeutics stock is up, what you need to know

Nurix Therapeutics (NRIX) shares fell 38% after Sanofi (SNY) terminated development of a key Phase I immunology candidate, SAR448272 (NX-3911), under their collaboration. Despite this, the rest of the collaboration remains intact, and Nurix maintains a strong cash position. Analysts note Nurix's potential in the oral protein degrader space, particularly its partnership with Roche (RO) for bexobrutideg (NX-5948), which targets a $48B market opportunity across five diseases.

Nurix Therapeutics (NRIX) shares dropped 38% in after-hours trading on Tuesday after Sanofi (SAN) decided to halt the Phase I trial of SAR448272, an oral STAT6 degrader. Sanofi notified Nurix of the decision to discontinue the clinical trial.

Nurix Therapeutics (NASDAQ:NRIX) will present Phase 1a/1b study data for bexobrutideg at the ASH meeting in December 2026. The data shows clinical activity and tolerability at 600 mg daily. The drug is being developed with Roche for treating relapsed/refractory CLL and SLL. Nurix is also conducting multiple clinical trials, including Phase 2 and 3 studies.

Sanofi terminated the phase 1 trial of SAR448272, an anti-STAT6 molecule developed with Nurix Therapeutics. Nurix will not receive further milestone payments or royalties, causing its stock to fall about 38% after hours, according to Reuters. Nurix maintains funding through 2029.

Sanofi has decided to halt studies of an experimental inflammatory disease therapy developed in partnership with Nurix Therapeutics. Nurix Therapeutics announced the decision on Tuesday, which led to a decline in its stock price in premarket trading on Wednesday.

Nurix Therapeutics (NRIX) shares fell sharply after Sanofi discontinued a clinical trial for a licensed drug. Analysts at Wells Fargo reduced their price target. The company relies on collaboration payments from partners like Roche, Gilead, and Pfizer. NRIX stock is down 16% year-to-date. Retail traders on Stocktwits showed bullish sentiment despite the setback.